Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Clin Gastroenterol Hepatol. 2021 Aug;19(8):1730-1732.e2. doi: 10.1016/j.cgh.2021.02.004. Epub 2021 Feb 4.
Patients with inflammatory bowel disease (IBD) develop coronavirus disease 2019 (COVID-19) at similar rates as the general population, and there was initial concern regarding potential for severe illness. Vaccinations were authorized for emergency use in the United States in December 2020 and aim to halt the spread of COVID-19. However, there are concerns that people will be hesitant to receive the vaccine for a variety of reasons including insufficient data in certain populations including those with IBD. We surveyed patients with IBD to identify potential concerns regarding COVID-19 vaccination.
患有炎症性肠病 (IBD) 的患者感染 2019 年冠状病毒病 (COVID-19) 的比率与一般人群相似，最初人们担心可能会出现重症。疫苗于 2020 年 12 月在美国获准紧急使用，旨在阻止 COVID-19 的传播。然而，人们担心出于各种原因，包括某些人群（包括 IBD 患者）的数据不足，人们会不愿意接种疫苗。我们调查了 IBD 患者，以确定他们对 COVID-19 疫苗接种的潜在担忧。
